Veterans with obesity report poorer health status and more disability days compared to veterans without obesity
The SELECT trial is a major breakthrough, says Yale Medicine cardiologist Harlan Krumholz, MD, SM, explaining that while semaglutide [given as Ozempic] was already known to lower the risk of heart disease in people with diabetes, the SELECT trial was the first to show that Wegovy, which contains a higher dose of semaglutide, also lowers that risk even in people who dont have diabetes
[25] [26] Appropriate ophthalmological monitoring is advisable in those with pre-existing retinopathy
For researchers already on tirzepatide considering a switch, understanding the transition timeline from tirzepatide to retatrutide helps with budget planning, since there may be an overlap period during the switch
Error 1: using the old concentration with a new vial This is the most dangerous mistake